Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer

NCT06532617 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neoplasms

Interventions

DRUG: Cadonilimab+S-1or Capecitabine

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine